Aclaris Therapeutics Inc (NASDAQ:ACRS) shares, rose in value, with the stock price down by -4.10% to the previous day’s close as strong demand from buyers drove the stock to $1.17.
Actively observing the price movement in the last trading, the stock closed the session at $1.22. Referring to stock’s 52-week performance, its high was $11.12, and the low was $0.59. On the whole, ACRS has fluctuated by 0.86% over the past month.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 5.58M, with a low estimate of 570k and a high estimate of 1.87M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 1.37M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ACRS’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a 50% Sell.
The stock’s technical analysis shows that the PEG ratio is about 0, with the price of ACRS currently trading nearly -3.98% and -4.18% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 43.10, while the 7-day volatility ratio is showing 4.39% which for the 30-day chart, stands at 5.01%. Furthermore, Aclaris Therapeutics Inc (ACRS)’s beta value is 0.24, and its average true range (ATR) is 0.07.
A comparison of Aclaris Therapeutics Inc (ACRS) with its peers suggests the former has fared considerably weaker in the market. ACRS showed an intraday change of -4.10% in last session, and over the past year, it shrunk by -87.11%%.
Data on historical trading for Aclaris Therapeutics Inc (NASDAQ:ACRS) indicates that the trading volumes over the past 3 months, they’ve averaged 1.07 million. According to company’s latest data on outstanding shares, there are 70.89 million shares outstanding.
Nearly 9.10% of Aclaris Therapeutics Inc’s shares belong to company insiders and institutional investors own 89.13% of the company’s shares. The stock has risen by 11.43% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ACRS stock heading into the next quarter.
